Các tác động lâm sàng của các đột biến di truyền trong ung thư vú: TP53

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339 Li FP, Fraumeni JF (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4):747–752 Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358–5362 Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res 54(5):1298–1304 Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:101–124 Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):e108–e109 author reply e110 Lalloo F, Varley J, Ellis D, Moran A, O’Dair L, Pharoah P et al (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet Lond Engl 361(9363):1101–1102 Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ et al (2009) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256 Bodian DL, McCutcheon JN, Kothiyal P, Huddleston KC, Iyer RK, Vockley JG et al (2014) Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PLoS ONE 9(4):e94554 Lee DSC, Yoon S-Y, Looi LM, Kang P, Kang IN, Sivanandan K et al (2012) Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res BCR 14(2):R66 Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MRE et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian breast cancer family study. Cancer Res 70(12):4795–4800 McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA et al (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11(4):607–613 Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D et al (2009) High frequency of de novo mutations in Li–Fraumeni syndrome. J Med Genet 46(10):689–693 Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123(10):1721–1730 Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA et al (2016) Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. Breast Cancer Res Treat. doi:10.1007/s10549-016-4038-y Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG et al (2015) Multigene panel testing detects equal rates of pathogenic BRCA1/2 Mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 22(10):3282–3288 Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L et al (2016) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18(8):823–832 Achatz MI, Zambetti GP (2016) The inherited p53 mutation in the Brazilian population. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a026195 Malkin D (2011) Li–Fraumeni syndrome. Genes Cancer 2(4):475–484 Andrade KC, Santiago KM, Fortes FP, Mambelli LI, Nóbrega AF, Achatz MI (2016) Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p. R337H mutation. Genet Mol Biol 39(2):199–202 Giacomazzi J, Correia RL, Palmero EI, Gaspar JF, Almeida M, Portela C et al (2014) The Brazilian founder mutation TP53 p. R337H is uncommon in Portuguese women diagnosed with breast cancer. Breast J 20(5):534–536 Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT et al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li–Fraumeni syndrome cohort. Cancer 122:3673–3681 Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P et al (2003) Li–Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63(20):6643–6650 Wu C-C, Krahe R, Lozano G, Zhang B, Wilson CD, Jo E-J et al (2011) Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li–Fraumeni syndrome. Hum Genet 129(6):663–673 Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP (1998) Multiple primary cancers in families with Li–Fraumeni syndrome. J Natl Cancer Inst 90(8):606–611 Ruijs MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FBL et al (2010) TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47(6):421–428 Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J et al (2016) TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37(9):865–876 Schneider K, Zelley K, Nichols KE, Garber J. Li–Fraumeni Syndrome (1993). In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK1311/. Accessed 5 Dec 2016 Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ et al (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome. Oncogene 17(9):1061–1068 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | 1-Recommendations | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/cg164/chapter/1-recommendations. Accessed 1 Dec 2016 National Comprehensive Cancer Network (2014) Genetic/familial high risk assessment: breast and ovarian. Li Fraumeni syndrome management. NCCN Clinical Practice Guidelines in Oncology; Version 2. 2014 eviQ Cancer Treatments Online (2016) Risk management for Li–Fraumeni syndrome. http://www.eviq.org.au. Accessed 12 Dec 2016 Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L et al (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li–Fraumeni syndrome. Radiat Oncol Lond Engl 5:104 Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):1125–1130 Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM et al (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908–913 Lammens CRM, Bleiker EMA, Aaronson NK, Wagner A, Sijmons RH, Ausems MGEM et al (2010) Regular surveillance for Li–Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer 9(4):647–654 Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17(9):1295–1305 Custódio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R et al (2013) Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol 31(20):2619–2626 Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J et al (2017) Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Fam Cancer 16:433 McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MHN, Eeles RA et al (2014) Li–Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11(5):260–271 Ballinger ML, Mitchell G, Thomas DM (2015) Surveillance recommendations for patients with germline TP53 mutations. Curr Opin Oncol 27(4):332–337 US National Libary of Medicine. ClinicalTrials.gov (2014). http://clinicaltrials.gov/show/NCT01464086. Accessed 13 Dec 2016 ANZCTR: Australia New Zealand Clinical Trials Registry. Trial from ANZCTR (2013). http://www.ANZCTR.org.au/ACTRN12613000987763.aspx. Accessed 13 Dec 2016 Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7(9):867–885 US National Libary of Medicine. ClinicalTrials.gov (2013). http://clinicaltrials.gov/show/NCT01981525. Accessed 13 Dec 2016